Compare ENLV & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENLV | INTS |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 24.0M |
| IPO Year | 1995 | 2023 |
| Metric | ENLV | INTS |
|---|---|---|
| Price | $0.83 | $0.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $4.33 |
| AVG Volume (30 Days) | ★ 11.7M | 3.2M |
| Earning Date | 11-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $0.19 |
| 52 Week High | $2.10 | $3.17 |
| Indicator | ENLV | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 47.25 |
| Support Level | $0.80 | $0.40 |
| Resistance Level | $0.88 | $0.43 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.69 | 20.02 |
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.